\
&
Contact us
\
&
Contact us
This was 11 months ago
LocationPermanent Representation of Estonia to the EU, Brussels
Estonian Research Council Brussels Office and ScanBalt® are organising a seminar on the 13th of May 2025 to address the pressing need for innovation in the early diagnosis of Alzheimer’s and Parkinson’s disease.
Policymakers, industry experts and academia will collaborate to explore how to bridge policy, technology and healthcare for the future of neurogenerative disease diagnosis and care in Europe.
The seminar (12:30-17:45) will be followed by a networking reception (17:45-18:30).
You can find more information and the registration link here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
